Cervical cancer and precancerous lesions
Conditions
Interventions
HPV vaccination:HPV testing
control:HPV testing
Sponsors
Peking Union Medical College
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria for population study after HPV vaccination: Vaccination group: 1. Complete at least one shot of vaccination; 2. I have informed consent and signed the informed consent form; 3. Subjects themselves can comply with the requirements of the protocol and complete all research procedures; 4. Have sex; 5. No other HPV vaccine products (including marketed and unlisted vaccines) have been used since the third phase clinical trial; 6. Agree not to use any HPV vaccine products (including marketed and unlisted vaccines) in the next 2 years; 7. Other conditions specified in the study protocol. Non vaccinated group: 1. Never used other HPV vaccine products (including marketed and unlisted vaccines); 2. I have informed consent and signed the informed consent form; 3. Subjects themselves can comply with the requirements of the protocol and complete all research procedures; 4. Have sex; 5. Agree not to use any HPV vaccine products (including marketed and unlisted vaccines) in the next 2 years; 6. Other conditions specified in the research protocol. Inclusion criteria of AI auxiliary diagnostic technology R&D and evaluation: 1. Women of 25-64 years old, in good health, with complete cervix; 2. Be able to understand the research procedure, voluntarily participate in and sign the informed consent form; 3. About 90% of women qualified for colposcopy were referred due to abnormal cytology and HPV detection, and about 10% of women with other cervical history and signs were willing to undergo colposcopy and histological biopsy.
Exclusion criteria
Exclusion criteria: 1. Women with clinically suspected pregnancy symptoms or within 8 weeks after delivery; 2. Have a history of cervical surgery or pelvic radiotherapy; 3. Have a clear history of cervical cancer and precancerous lesions; 4. Those who are physically or mentally unable to accept routine examinations or cannot provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV infection; | — |
Secondary
| Measure | Time frame |
|---|---|
| Antibody of HPV 16/18; | — |
Countries
China
Contacts
Public ContactYoulin Qiao
Peking Union Medical College
Outcome results
None listed